ClinicalTrials.gg
CompletedNCT02133742Updated Jul 28, 2021Results posted

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

A Phase 1 interventional study of Axitinib and MK-3475 in Renal Cell Carcinoma, sponsored by Pfizer. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-28.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing axitinib in Carcinoma, Renal Cell — 11 open to participants now, 15 under way, 1 of them phase 3. Axitinib · Carcinoma, Renal Cell.

Enrollment
14th of 41
52 · median 40
Started
2014
the only one that year
Phase 1
3 of 41
none open now
Registered
10th of 41
by date
Lead sponsor
6 of 41
Pfizer

Among the 41 studies testing axitinib in Carcinoma, Renal Cell, this one is the 14th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 1, and was the 10th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 41 studies testing axitinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About axitinib

Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing axitinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Despite substantial improvements of patients outcome in advanced RCC, durable and complete response is uncommon. The majority of patients eventually develop resistance and exhibit disease progression. Combining a PD-1 inhibitor, which has shown single-agent efficacy with axitinib may provide additional clinical benefit compared to axitinib alone.

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Axitinib and MK-3475
  • patients with advanced Renal Cell Cancer.
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced RCC with predominantly clear-cell subtype with primary tumor resected
  • At least one measureable lesion as defined by (RECIST) version 1.1.
  • performance status 0 or 1
  • Controlled hypertension

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with systemic therapy for advanced RCC
  • Prior or neoadjuvant therapy if disease progression or relapse has occurred during or within 12 months after the last dose of treatment
  • Prior treatment with any agent specifically targeting T-cell co-stimulation or checkpoint pathways
  • Active seizure disorder or evidence of , spinal cord compression, or carcinomatous meningitis
  • Diagnosis of any non-RCC occurring within 2 years prior to the date of randomization except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix or low grade prostate cancer with no plans for treatment intervention
  • In past 12 months: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or
  • In past 6 months: deep vein thrombosis or pulmonary embolism
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Dose finding phase and dose expansion phase

    To test the maximum tolerated dose of MK-3475 at 2 mg/kg every three weeks intravenous infusion in combination with approved axitinib dose

    Drug: Axitinib · Drug: MK-3475

Interventions

  • Axitinib at starting dose of 5 mg and 3 mg BID.

  • MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLT): Dose Finding Phase

    DLT was defined as any of the following adverse events (AEs) occurring in the first two cycles of treatment which were attributable to one or both the study drugs: 1) Grade 4 neutropenia, 2) Febrile neutropenia lasting greater than (\>) 1 hour, 3) Grade greater than or equal to (\>=) 3 neutropenia with infection, 4) Grade \>=3 thrombocytopenia with bleeding, 4) Grade 4 thrombocytopenia, 5) Any grade \>=3 non-hematologic: non-laboratory toxicities despite maximum supportive therapy or hypertension despite maximal medical therapy, 6) Grade \>=3 non-hematologic toxicities resulted in hospitalisation or medical intervention 7) Inability to complete at least 75 percent (%) of axitinib dosing or 2 infusions of pembrolizumab within the DLT observation period (up to 42 days) due to treatment related toxicity. Severity of AEs was graded according to NCI (National Cancer Institute) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: Cycle 1 Day 1 to Cycle 2 Day 21 (up to 42 days)

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant and jeopardized the participants or required treatment to prevent other AE outcomes for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events which occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.

    Time frame: Baseline up to 28 days after last dose of study drug (approximately up to 1552 days)

  2. Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant and jeopardized the participants or required treatment to prevent other AE outcomes for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events which occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.

    Time frame: Baseline up to 28 days after last dose of study drug (approximately up to 1552 days)

  3. Number of Participants With Adverse Events (AEs) According to Severity of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant and jeopardized the participants or required treatment to prevent other AE outcomes for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were graded according to the Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and coded using the Medical Dictionary for Regulatory Activities (MedDRA) as Grade 3: Severe, Grade 4: Life threatening, Grade 5: Death related to AE. Participants were counted once according to the maximum grade observed.

    Time frame: Baseline up to 28 days after last dose of study drug (approximately up to 1552 days)

  4. Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Hematology

    Laboratory parameters included hematological and biochemistry parameters. Biochemistry parameters included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia. Hematology parameters included anemia, haemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets and white blood cells. Test abnormalities were graded by NCI CTCAE version 4.03 as Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Only categories with at least 1 participant with abnormality are reported in this outcome measure.

    Time frame: Baseline up to a maximum of 1083 days

  5. Number of Participants With Laboratory Test Abnormalities: Urinalysis

    Urinalysis parameter included urine protein, urine blood/hemoglobin and urine glucose. Test abnormalities was defined as deviation from normal range. Normal range of 24-hour urine protein test: less than 150 mg of protein per day, urine glucose: 0 to 0.8 mmol/L (millimoles per liter), urine protein: 0 to 20 mg/dL (milligrams per deciliter). Urine blood/hemoglobin abnormality was defined as presence and absence of blood/hemoglobin in urine of participants.

    Time frame: Baseline up to a maximum of 1083 days

  6. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs included blood pressure, pulse rate and weight. Change from baseline values were considered to be clinically significant based on investigator's judgement.

    Time frame: Baseline up to a maximum of 1083 days

  7. Number of Participants With Eastern Cooperative Oncology Group [ECOG] Performance Status Score

    ECOG performance status was used to assess how disease affect the daily living abilities of a participant. It was measured on a scale ranging from 0 to 4, where 0=fully active (able to carry on all pre-disease activities without restriction); 1=restricted in physically strenuous activity but ambulatory (able to carry out light/sedentary work); 2=ambulatory and capable of all self-care but unable to carry out any work activities (for more than 50% of waking hours); 3=capable of limited self-care, confined to bed or chair (for \>50% of waking hours); 4=completely disabled, not capable of any self-care, totally confined to bed or chair. Higher scores signified =more functional impairment of a participant.

    Time frame: Baseline up to Cycle 43 (up to 1083 days)

  8. Objective Response Rate

    Objective response rate was defined as percentage of participants with confirmed complete response (CR) or confirmed partial response (PR), as assessed by response evaluation criteria in solid tumors (RECIST) version 1.1. Confirmed responses were those that persist on repeated imaging for at least 4 weeks after initial documentation of response. CR was defined as disappearance of all target lesions and the reduction in short axis of any pathological lymph nodes to \<10 mm. PR was defined as a 30% or more decrease in the sum of longest dimensions of the target lesions, taking as reference the baseline sum of longest dimensions.

    Time frame: Baseline until disease progression or death due to any cause, up to a maximum of 1083 days

  9. Duration of Response (DR)

    DR:date of first documentation of objective tumour response(OR) confirmed to date of first documentation of PD/death due to any cause,whichever occurred first.PD per RECIST 1.1:\>=20%increase in sum of longest dimensions(LD) of target lesions,reference to smallest sum of LD recorded since treatment started/appearance of 1 or more new lesions/increase of at least 5mm addition to relative increase of 20%.DR calculated only for participants with confirmed OR.Participants lacking evaluation of tumour response after date of first study drug dose was censored on date of first dose unless death occurred prior to 18 weeks.If participants had at least 1 on-study assessment,PFS was censored on date of last evaluable tumour disease assessment documenting absence of PD for participants who were alive and progression free at time of analysis/had documentation of PD/death after\>=2 consecutive missed tumour assessments/given anti-tumour treatment other than study drug prior to documented PD/death.

    Time frame: Baseline until disease progression or death due to any cause, up to a maximum of 1083 days

  10. Time to Response (TTR)

    TTR was defined as the time from first dose of study treatment to the first documentation of objective tumor response (CR or PR) that was subsequently confirmed.

    Time frame: Baseline until disease progression or death due to any cause, up to a maximum of 1083 days

  11. Progression-Free Survival (PFS)

    PFS: time from date of first dose of study drug to the date of first documented PD or death on study due to any cause. PD as per RECIST v1.1 defined as at least a 20% increase in sum of longest dimensions of target lesions, reference to smallest sum of longest dimensions recorded since treatment started, or appearance of 1 or more new lesions or increase of at least 5 mm in addition to relative increase of 20%. Participants lacking an evaluation of tumor response after date of first study drug dose had event time censored on date of first dose unless death occurred prior to 18 weeks. If participants had at least 1 on-study assessment, PFS data was censored on date of last evaluable tumor disease assessment documenting absence of PD for participants who were alive and progression free at the time of analysis or had documentation of PD or had death after \>=2 consecutive missed tumor assessments or were given anti-tumor treatment other than study drug prior to documented PD or death.

    Time frame: Baseline until disease progression or death due to any cause, up to a maximum of 1083 days

  12. Overall Survival (OS)

    OS was defined as the time from the first dose of study drug to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive.

    Time frame: Baseline until disease progression or death due to any cause, up to a maximum of 1552 days

  13. Maximum Observed Plasma Concentration (Cmax) of Axitinib

    Time frame: Dose Finding Phase:Pre-dose,1,2,3,4,6,8 hours (hrs) post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1;Dose Expansion Phase:Pre dose,1,2,3,4,6,8 hrs post dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1

  14. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib

    Time frame: Dose Finding Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1; Dose Expansion Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1

  15. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC 0-12) of Axitinib

    Time frame: Dose Finding Phase:Pre-dose, 1, 2, 3, 4,6,8, 12 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1; Dose Expansion Phase:Pre-dose, 1,2,3,4,6,8,12 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1

  16. Apparent Oral Clearance (CL/F) of Axitinib

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes).

    Time frame: Dose Finding Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1; Dose Expansion Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1

  17. Apparent Volume of Distribution (Vz/F) of Axitinib

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Dose Finding Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1; Dose Expansion Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1

  18. Number of Participants With Positive Anti-Drug Antibodies (ADA) of Pembrolizumab (MK-3475)

    Time frame: Day 1 of Cycle 1 up to Day 21 of Cycle 56 (up to 1176 days)

  19. Number of Participants With Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score

    PD-L1- tumor proportion score was defined as the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. Participants with positive or negative scores were reported. PD-L1 negative: if tumor proportion score was less than 1%; PD-L1 positive: if the tumor proportion score greater than or equal to 1%.

    Time frame: Baseline up to Cycle 43 (up to 1083 days)

  20. Number of Participants With Vascular Endothelial Growth Factor A (VEGF-A) Tumor Proportion Score

    Vascular Endothelial Growth Factor (VEGF) promotes cancer progression by inducing angiogenesis via VEGF receptors, signals directly through receptors VEGFR-1 and VEGFR-2. Change in biomarkers related to VEGFR signal transduction pathways after axitinib treatment was assessed. Plasma VEGF concentration evaluations were performed using samples from peripheral blood plasma, bone marrow aspirate, bone marrow (Core) biopsy and bone marrow clot. The VEGFR, axitinib and mechanistic target of rapamycin inhibitor everolimus are used individually in subsequent lines of therapy for advanced clear cell renal cell carcinoma (ccRCC).

    Time frame: Baseline up to Cycle 64 (up to 1344 days)

  21. Concentration of Vascular Endothelial Growth Factor A (VEGF-A) in Serum

    Vascular endothelial growth factor (VEGF) promotes cancer progression by inducing angiogenesis via VEGF receptors, signals directly through receptors VEGFR-1 and VEGFR-2. Change in biomarkers related to VEGFR signal transduction pathways after axitinib treatment was assessed. Mononuclear (MNC) cell VEGF receptor expression and phosphorylation was assessed by in situ western blot analysis. VEGFR-1 and VEGFR-2 evaluations were performed using samples from peripheral blood plasma, bone marrow aspirate, bone marrow (Core) biopsy and bone marrow clot. The VEGFR, axitinib and mechanistic target of rapamycin inhibitor everolimus are used individually in subsequent lines of therapy for advanced clear cell renal cell carcinoma (ccRCC).

    Time frame: Baseline, Day 1 of Cycle 2 Pre-dose, Post end of treatment or Withdrawal whichever came first (maximum of 1344 days)

  22. Concentration of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in Serum

    Vascular endothelial growth factor (VEGF) promotes cancer progression by inducing angiogenesis via VEGF receptors, signals directly through receptors VEGFR-1 and VEGFR-2. Change in biomarkers related to VEGFR signal transduction pathways after axitinib treatment was assessed. Mononuclear (MNC) cell VEGF receptor expression and phosphorylation was assessed by in situ western blot analysis. VEGFR-1 and VEGFR-2 evaluations were performed using samples from peripheral blood plasma, bone marrow aspirate, bone marrow (Core) biopsy and bone marrow clot. The VEGFR, axitinib and mechanistic target of rapamycin inhibitor everolimus are used individually in subsequent lines of therapy for advanced clear cell renal cell carcinoma (ccRCC).

    Time frame: Baseline, Day 1 of Cycle 2 Pre-dose, Post end of treatment or Withdrawal whichever came first (maximum of 1344 days)

  23. Concentration of Interleukin 8 (IL-8) in Serum

    Time frame: Baseline, Day 1 of Cycle 2 Pre-dose, Post end of treatment or Withdrawal whichever came first (maximum of 1344 days)

07

Results

Posted Jun 21, 2019

Participant flow

Period 1: Dose Finding Phase (6 Months)
Participant flow — Period 1: Dose Finding Phase (6 Months)
MilestoneAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Started11
Completed11
Not completed0
Period 2:Dose Expansion Phase (1344days)
Participant flow — Period 2:Dose Expansion Phase (1344days)
MilestoneAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Started52
Completed0
Not completed52
Withdrew: Lost to follow-up2
Withdrew: End of survival follow-up/treatment31
Withdrew: Death13
Withdrew: Participant refused further follow-up5
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLT): Dose Finding Phase

DLT was defined as any of the following adverse events (AEs) occurring in the first two cycles of treatment which were attributable to one or both the study drugs: 1) Grade 4 neutropenia, 2) Febrile neutropenia lasting greater than (\>) 1 hour, 3) Grade greater than or equal to (\>=) 3 neutropenia with infection, 4) Grade \>=3 thrombocytopenia with bleeding, 4) Grade 4 thrombocytopenia, 5) Any grade \>=3 non-hematologic: non-laboratory toxicities despite maximum supportive therapy or hypertension despite maximal medical therapy, 6) Grade \>=3 non-hematologic toxicities resulted in hospitalisation or medical intervention 7) Inability to complete at least 75 percent (%) of axitinib dosing or 2 infusions of pembrolizumab within the DLT observation period (up to 42 days) due to treatment related toxicity. Severity of AEs was graded according to NCI (National Cancer Institute) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
Cycle 1 Day 1 to Cycle 2 Day 21 (up to 42 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLT): Dose Finding Phase
ParticipantsAxitinib 5 mg + Pembrolizumab 2 mg: Dose Finding Phase
Number of Participants With Dose-Limiting Toxicities (DLT): Dose Finding Phase3
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant and jeopardized the participants or required treatment to prevent other AE outcomes for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events which occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.

Time frame:
Baseline up to 28 days after last dose of study drug (approximately up to 1552 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
AEs52
SAEs29
SecondaryNumber of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant and jeopardized the participants or required treatment to prevent other AE outcomes for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events which occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.

Time frame:
Baseline up to 28 days after last dose of study drug (approximately up to 1552 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
AEs52
SAEs23
SecondaryNumber of Participants With Adverse Events (AEs) According to Severity of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant and jeopardized the participants or required treatment to prevent other AE outcomes for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were graded according to the Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and coded using the Medical Dictionary for Regulatory Activities (MedDRA) as Grade 3: Severe, Grade 4: Life threatening, Grade 5: Death related to AE. Participants were counted once according to the maximum grade observed.

Time frame:
Baseline up to 28 days after last dose of study drug (approximately up to 1552 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) According to Severity of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03
ParticipantsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Grade 3 or 438
Grade 51
SecondaryNumber of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Hematology

Laboratory parameters included hematological and biochemistry parameters. Biochemistry parameters included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia. Hematology parameters included anemia, haemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets and white blood cells. Test abnormalities were graded by NCI CTCAE version 4.03 as Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Only categories with at least 1 participant with abnormality are reported in this outcome measure.

Time frame:
Baseline up to a maximum of 1083 days
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Hematology
ParticipantsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Alanine aminotransferase: Grade 32
Hypercalcemia: Grade 31
Hyperglycemia: Grade 35
Hyperkalemia: Grade 31
Hypermagnesemia; Grade 31
Hypokalemia: Grade 33
Hyponatremia: Grade 34
Hypophosphatemia: Grade 37
Lymphopenia: Grade 34
Neutrophils (absolute): Grade 32
SecondaryNumber of Participants With Laboratory Test Abnormalities: Urinalysis

Urinalysis parameter included urine protein, urine blood/hemoglobin and urine glucose. Test abnormalities was defined as deviation from normal range. Normal range of 24-hour urine protein test: less than 150 mg of protein per day, urine glucose: 0 to 0.8 mmol/L (millimoles per liter), urine protein: 0 to 20 mg/dL (milligrams per deciliter). Urine blood/hemoglobin abnormality was defined as presence and absence of blood/hemoglobin in urine of participants.

Time frame:
Baseline up to a maximum of 1083 days
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities: Urinalysis
ParticipantsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Urine protein (24 hrs)0
Urine blood/hemoglobin11
Urine glucose9
Urine protein25
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs included blood pressure, pulse rate and weight. Change from baseline values were considered to be clinically significant based on investigator's judgement.

Time frame:
Baseline up to a maximum of 1083 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Number of Participants With Clinically Significant Change From Baseline in Vital Signs0
SecondaryNumber of Participants With Eastern Cooperative Oncology Group [ECOG] Performance Status Score

ECOG performance status was used to assess how disease affect the daily living abilities of a participant. It was measured on a scale ranging from 0 to 4, where 0=fully active (able to carry on all pre-disease activities without restriction); 1=restricted in physically strenuous activity but ambulatory (able to carry out light/sedentary work); 2=ambulatory and capable of all self-care but unable to carry out any work activities (for more than 50% of waking hours); 3=capable of limited self-care, confined to bed or chair (for \>50% of waking hours); 4=completely disabled, not capable of any self-care, totally confined to bed or chair. Higher scores signified =more functional impairment of a participant.

Time frame:
Baseline up to Cycle 43 (up to 1083 days)
Reported as:
Count of participants · Participants
Number of Participants With Eastern Cooperative Oncology Group [ECOG] Performance Status Score
ParticipantsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
039
110
20
30
40
Missing3
SecondaryObjective Response Rate

Objective response rate was defined as percentage of participants with confirmed complete response (CR) or confirmed partial response (PR), as assessed by response evaluation criteria in solid tumors (RECIST) version 1.1. Confirmed responses were those that persist on repeated imaging for at least 4 weeks after initial documentation of response. CR was defined as disappearance of all target lesions and the reduction in short axis of any pathological lymph nodes to \<10 mm. PR was defined as a 30% or more decrease in the sum of longest dimensions of the target lesions, taking as reference the baseline sum of longest dimensions.

Time frame:
Baseline until disease progression or death due to any cause, up to a maximum of 1083 days
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Objective Response Rate73.1 (59.0 to 84.4)
SecondaryDuration of Response (DR)

DR:date of first documentation of objective tumour response(OR) confirmed to date of first documentation of PD/death due to any cause,whichever occurred first.PD per RECIST 1.1:\>=20%increase in sum of longest dimensions(LD) of target lesions,reference to smallest sum of LD recorded since treatment started/appearance of 1 or more new lesions/increase of at least 5mm addition to relative increase of 20%.DR calculated only for participants with confirmed OR.Participants lacking evaluation of tumour response after date of first study drug dose was censored on date of first dose unless death occurred prior to 18 weeks.If participants had at least 1 on-study assessment,PFS was censored on date of last evaluable tumour disease assessment documenting absence of PD for participants who were alive and progression free at time of analysis/had documentation of PD/death after\>=2 consecutive missed tumour assessments/given anti-tumour treatment other than study drug prior to documented PD/death.

Time frame:
Baseline until disease progression or death due to any cause, up to a maximum of 1083 days
Reported as:
Median · months
Duration of Response (DR)
monthsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Duration of Response (DR)18.6 (15.1 to NA)
SecondaryTime to Response (TTR)

TTR was defined as the time from first dose of study treatment to the first documentation of objective tumor response (CR or PR) that was subsequently confirmed.

Time frame:
Baseline until disease progression or death due to any cause, up to a maximum of 1083 days
Reported as:
Median · months
Time to Response (TTR)
monthsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Time to Response (TTR)2.8 (0.7 to 15.2)
SecondaryProgression-Free Survival (PFS)

PFS: time from date of first dose of study drug to the date of first documented PD or death on study due to any cause. PD as per RECIST v1.1 defined as at least a 20% increase in sum of longest dimensions of target lesions, reference to smallest sum of longest dimensions recorded since treatment started, or appearance of 1 or more new lesions or increase of at least 5 mm in addition to relative increase of 20%. Participants lacking an evaluation of tumor response after date of first study drug dose had event time censored on date of first dose unless death occurred prior to 18 weeks. If participants had at least 1 on-study assessment, PFS data was censored on date of last evaluable tumor disease assessment documenting absence of PD for participants who were alive and progression free at the time of analysis or had documentation of PD or had death after \>=2 consecutive missed tumor assessments or were given anti-tumor treatment other than study drug prior to documented PD or death.

Time frame:
Baseline until disease progression or death due to any cause, up to a maximum of 1083 days
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Progression-Free Survival (PFS)20.9 (15.4 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the first dose of study drug to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive.

Time frame:
Baseline until disease progression or death due to any cause, up to a maximum of 1552 days
Reported as:
Median · months
Overall Survival (OS)
monthsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Overall Survival (OS)NA (43.7 to NA)
SecondaryMaximum Observed Plasma Concentration (Cmax) of Axitinib
Time frame:
Dose Finding Phase:Pre-dose,1,2,3,4,6,8 hours (hrs) post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1;Dose Expansion Phase:Pre dose,1,2,3,4,6,8 hrs post dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Axitinib
nanogram per milliliter (ng/mL)Axitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Dose finding phase: Day 7 of Lead-in46.58 ± 58
Dose finding phase: Day 1 of cycle 736.57 ± 31
Dose expansion phase: Day 7 of Lead-in24.83 ± 85
Dose expansion phase: Day 1 of cycle 722.65 ± 51
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib
Time frame:
Dose Finding Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1; Dose Expansion Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib
hourAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Dose finding phase: Day 7 of Lead-in2.00 (1.00 to 4.00)
Dose finding phase: Day 1 of cycle 73.00 (3.00 to 4.00)
Dose expansion phase: Day 7 of Lead-in2.00 (0.000 to 3.00)
Dose expansion phase: Day 1 of cycle 72.00 (1.00 to 4.00)
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUC 0-12) of Axitinib
Time frame:
Dose Finding Phase:Pre-dose, 1, 2, 3, 4,6,8, 12 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1; Dose Expansion Phase:Pre-dose, 1,2,3,4,6,8,12 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC 0-12) of Axitinib
nanogram*hour per milliliter (ng*hr/mL)Axitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Dose finding phase: Day 7 of Lead-in199.1 ± 46
Dose finding phase: Day 1 of cycle 7219.4 ± 12
Dose expansion phase: Day 7 of Lead-in92.99 ± 142
Dose expansion phase: Day 1 of cycle 7116.9 ± 50
SecondaryApparent Oral Clearance (CL/F) of Axitinib

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes).

Time frame:
Dose Finding Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1; Dose Expansion Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1
Reported as:
Geometric mean · liter per hour (L/hr)
Apparent Oral Clearance (CL/F) of Axitinib
liter per hour (L/hr)Axitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Dose finding phase: Day 7 of Lead-in25.11 ± 46
Dose finding phase: Day 1 of cycle 722.79 ± 12
Dose Expansion Phase: Day 7 of Lead-in53.77 ± 142
Dose expansion phase: Day 1 of cycle 742.79 ± 50
SecondaryApparent Volume of Distribution (Vz/F) of Axitinib

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Dose Finding Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1; Dose Expansion Phase:Pre-dose, 1, 2, 3, 4, 6, 8 hrs post-dose on Day 7 of Lead-in (7 days prior Cycle 1 Day 1), Cycle 7 Day 1
Reported as:
Geometric mean · liter
Apparent Volume of Distribution (Vz/F) of Axitinib
literAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Dose finding phase: Day 7 of Lead-in85.12 ± 36
Dose finding phase: Day 1 of cycle 750.91
Dose Expansion Phase: Day 7 of Lead-in245.8 ± 50
Dose expansion phase: Day 1 of cycle 7225.5
SecondaryNumber of Participants With Positive Anti-Drug Antibodies (ADA) of Pembrolizumab (MK-3475)
Time frame:
Day 1 of Cycle 1 up to Day 21 of Cycle 56 (up to 1176 days)
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Drug Antibodies (ADA) of Pembrolizumab (MK-3475)
ParticipantsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Number of Participants With Positive Anti-Drug Antibodies (ADA) of Pembrolizumab (MK-3475)3
SecondaryNumber of Participants With Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score

PD-L1- tumor proportion score was defined as the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. Participants with positive or negative scores were reported. PD-L1 negative: if tumor proportion score was less than 1%; PD-L1 positive: if the tumor proportion score greater than or equal to 1%.

Time frame:
Baseline up to Cycle 43 (up to 1083 days)
Reported as:
Count of participants · Participants
Number of Participants With Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score
ParticipantsAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Positive Score9
Negative Score34
Missing1
SecondaryNumber of Participants With Vascular Endothelial Growth Factor A (VEGF-A) Tumor Proportion Score

Vascular Endothelial Growth Factor (VEGF) promotes cancer progression by inducing angiogenesis via VEGF receptors, signals directly through receptors VEGFR-1 and VEGFR-2. Change in biomarkers related to VEGFR signal transduction pathways after axitinib treatment was assessed. Plasma VEGF concentration evaluations were performed using samples from peripheral blood plasma, bone marrow aspirate, bone marrow (Core) biopsy and bone marrow clot. The VEGFR, axitinib and mechanistic target of rapamycin inhibitor everolimus are used individually in subsequent lines of therapy for advanced clear cell renal cell carcinoma (ccRCC).

Time frame:
Baseline up to Cycle 64 (up to 1344 days)

No measurements were reported for this outcome.

SecondaryConcentration of Vascular Endothelial Growth Factor A (VEGF-A) in Serum

Vascular endothelial growth factor (VEGF) promotes cancer progression by inducing angiogenesis via VEGF receptors, signals directly through receptors VEGFR-1 and VEGFR-2. Change in biomarkers related to VEGFR signal transduction pathways after axitinib treatment was assessed. Mononuclear (MNC) cell VEGF receptor expression and phosphorylation was assessed by in situ western blot analysis. VEGFR-1 and VEGFR-2 evaluations were performed using samples from peripheral blood plasma, bone marrow aspirate, bone marrow (Core) biopsy and bone marrow clot. The VEGFR, axitinib and mechanistic target of rapamycin inhibitor everolimus are used individually in subsequent lines of therapy for advanced clear cell renal cell carcinoma (ccRCC).

Time frame:
Baseline, Day 1 of Cycle 2 Pre-dose, Post end of treatment or Withdrawal whichever came first (maximum of 1344 days)
Reported as:
Mean · picogram per millilitre (pg/mL)
Concentration of Vascular Endothelial Growth Factor A (VEGF-A) in Serum
picogram per millilitre (pg/mL)Axitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Baseline315.2 ± 286.6
Cycle 2 Day 1432.1 ± 315.0
End of treatment383.6 ± 360.4
SecondaryConcentration of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in Serum

Vascular endothelial growth factor (VEGF) promotes cancer progression by inducing angiogenesis via VEGF receptors, signals directly through receptors VEGFR-1 and VEGFR-2. Change in biomarkers related to VEGFR signal transduction pathways after axitinib treatment was assessed. Mononuclear (MNC) cell VEGF receptor expression and phosphorylation was assessed by in situ western blot analysis. VEGFR-1 and VEGFR-2 evaluations were performed using samples from peripheral blood plasma, bone marrow aspirate, bone marrow (Core) biopsy and bone marrow clot. The VEGFR, axitinib and mechanistic target of rapamycin inhibitor everolimus are used individually in subsequent lines of therapy for advanced clear cell renal cell carcinoma (ccRCC).

Time frame:
Baseline, Day 1 of Cycle 2 Pre-dose, Post end of treatment or Withdrawal whichever came first (maximum of 1344 days)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Concentration of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in Serum
nanogram per milliliter (ng/mL)Axitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Baseline4.11 ± 1.27
Cycle 2 Day 13.07 ± 0.93
End of treatment3.69 ± 1.41
SecondaryConcentration of Interleukin 8 (IL-8) in Serum
Time frame:
Baseline, Day 1 of Cycle 2 Pre-dose, Post end of treatment or Withdrawal whichever came first (maximum of 1344 days)
Reported as:
Mean · mmol/L
Concentration of Interleukin 8 (IL-8) in Serum
mmol/LAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
BaselineNA ± NA
Cycle 2 Day 1NA ± NA
End of treatmentNA ± NA

Adverse events

Collected over Baseline up to 28 days after last dose of study drug (approximately up to 1552 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib 5 mg + Pembrolizumab (MK-3475) 2 mg14/52 (26.9%)29/52 (55.8%)52/52 (100%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
DiarrhoeaGastrointestinal disorders6/52
DyspnoeaRespiratory, thoracic and mediastinal disorders4/52
ColitisGastrointestinal disorders3/52
Alanine aminotransferase increasedInvestigations3/52
Small intestinal obstructionGastrointestinal disorders2/52
VomitingGastrointestinal disorders2/52
FatigueGeneral disorders2/52
Pleural effusionRespiratory, thoracic and mediastinal disorders2/52
Atrial fibrillationCardiac disorders1/52
Atrial flutterCardiac disorders1/52
Most frequent other events
Showing 10 of 330
Most frequent other events
EventAxitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
DiarrhoeaGastrointestinal disorders44/52
FatigueGeneral disorders42/52
HypertensionVascular disorders28/52
CoughRespiratory, thoracic and mediastinal disorders25/52
DysphoniaRespiratory, thoracic and mediastinal disorders25/52
HypothyroidismEndocrine disorders23/52
NauseaGastrointestinal disorders23/52
Decreased appetiteMetabolism and nutrition disorders23/52
Alanine aminotransferase increasedInvestigations21/52
ConstipationGastrointestinal disorders19/52

Baseline characteristics

Safety analysis set included all enrolled participants in dose finding and dose expansion phases who received at least 1 dose of axitinib or pembrolizumab.

Age, Continuous
Age, Continuous(years)Axitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Mean61.2 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
Female11
Male41
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Axitinib 5 mg + Pembrolizumab (MK-3475) 2 mg
White45
Black1
Asian4
Other2
08

Study locations

19 sites
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • H. Lee Moffitt Cancer Center & Research Institute, Inc.
    Tampa, Florida 33612, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Attn. Alicia Sammarco, RPh, NYU Investigational Pharmacy
    New York, New York 10016, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • NYU Langone
    New York, New York 10016, United States
  • Investigational Drug Services
    Columbus, Ohio 43210, United States
  • James Cancer Hospital
    Columbus, Ohio 43210, United States
  • The Ohio State University Brain and Spine Hospital
    Columbus, Ohio 43210, United States
  • Martha Morehouse Medical Plaza
    Columbus, Ohio 43221, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Henry-Joyce Cancer Clinic
    Nashville, Tennessee 37232, United States
  • Vanderbilt Oncology Pharmacy
    Nashville, Tennessee 37232, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
09

References and documents

Publications

  • Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Tarazi JC, Duggan W, Perini R, Thakur M, Fernandez KC, Choueiri TK. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. Eur J Cancer. 2021 Mar;145:1-10. doi: 10.1016/j.ejca.2020.12.009. Epub 2021 Jan 4. PubMed 33412465 ↗
  • Martini JF, Plimack ER, Choueiri TK, McDermott DF, Puzanov I, Fishman MN, Cho DC, Vaishampayan U, Rosbrook B, Fernandez KC, Tarazi JC, George S, Atkins MB. Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clin Cancer Res. 2020 Nov 1;26(21):5598-5608. doi: 10.1158/1078-0432.CCR-20-1408. Epub 2020 Aug 18. PubMed 32816890 ↗
  • Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE, Tarazi JC, Rosbrook B, Fernandez KC, Lechuga M, Choueiri TK. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018 Mar;19(3):405-415. doi: 10.1016/S1470-2045(18)30081-0. Epub 2018 Feb 10. PubMed 29439857 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Mar 2017, 30 months.

Results were first posted in Jun 2019, 2 years 2 months after primary completion.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 30 months is below that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2014
First posted
May 8, 2014
StartActual
Sep 16, 2014
Primary completionActual
Mar 31, 2017
CompletionActual
Jul 3, 2019
Results first posted
Jun 21, 2019
Last update
Jul 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02133742
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 8, 2014
Start date
Sep 16, 2014
Primary completion
Mar 31, 2017
Completion
Jul 3, 2019
Results posted
Jun 21, 2019
Last update
Jul 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Axitinib · Pembrolizumab

Start the discussion